Covalon Technologies Ltd. (CVALF)
USD 1.7
(1.8%)
USD 1.7
(1.8%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -4.46 Million CAD | 53.84% |
| 2022 | -9.66 Million CAD | -141.16% |
| 2021 | 23.47 Million CAD | 400.51% |
| 2020 | -7.81 Million CAD | 22.09% |
| 2019 | -10.02 Million CAD | -719.85% |
| 2018 | 1.61 Million CAD | -10.71% |
| 2017 | 1.81 Million CAD | 158.53% |
| 2016 | -3.09 Million CAD | -228.58% |
| 2015 | -941.99 Thousand CAD | -139.22% |
| 2014 | 2.4 Million CAD | 341.83% |
| 2013 | -993.16 Thousand CAD | 75.12% |
| 2012 | -3.99 Million CAD | -12.06% |
| 2011 | -3.56 Million CAD | 9.48% |
| 2010 | -3.93 Million CAD | 19.28% |
| 2009 | -4.87 Million CAD | -30.31% |
| 2008 | -3.74 Million CAD | -21.6% |
| 2007 | -3.07 Million CAD | -39.52% |
| 2006 | -2.2 Million CAD | -18.45% |
| 2005 | -1.86 Million CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 1.44 Million CAD | -0.85% |
| 2024 Q1 | -851.54 Thousand CAD | 70.44% |
| 2024 Q2 | 1.46 Million CAD | 271.5% |
| 2023 Q2 | -674.37 Thousand CAD | -66.19% |
| 2023 Q4 | -2.88 Million CAD | -474.04% |
| 2023 Q3 | -501.76 Thousand CAD | 25.6% |
| 2023 FY | -4.46 Million CAD | 53.84% |
| 2023 Q1 | -405.78 Thousand CAD | 90.12% |
| 2022 Q3 | -1.63 Million CAD | 34.4% |
| 2022 Q4 | -4.1 Million CAD | -150.36% |
| 2022 Q2 | -2.5 Million CAD | -64.82% |
| 2022 Q1 | -1.51 Million CAD | -106.78% |
| 2022 FY | -9.66 Million CAD | -141.16% |
| 2021 Q2 | 421.72 Thousand CAD | 213.26% |
| 2021 Q1 | -372.34 Thousand CAD | 82.94% |
| 2021 Q3 | 1.05 Million CAD | 150.86% |
| 2021 FY | 23.47 Million CAD | 400.51% |
| 2021 Q4 | 22.36 Million CAD | 2014.47% |
| 2020 Q4 | -2.18 Million CAD | -794.86% |
| 2020 FY | -7.81 Million CAD | 22.09% |
| 2020 Q2 | -3.9 Million CAD | -232.72% |
| 2020 Q1 | -1.17 Million CAD | 66.58% |
| 2020 Q3 | 314.16 Thousand CAD | 108.04% |
| 2019 Q3 | -3.48 Million CAD | -1399.02% |
| 2019 Q2 | -232.22 Thousand CAD | 87.84% |
| 2019 Q1 | -1.9 Million CAD | -205.47% |
| 2019 FY | -10.02 Million CAD | -719.85% |
| 2019 Q4 | -3.51 Million CAD | -0.97% |
| 2018 Q1 | 523.34 Thousand CAD | 101.94% |
| 2018 Q2 | -479.08 Thousand CAD | -191.54% |
| 2018 Q3 | 2.19 Million CAD | 558.89% |
| 2018 Q4 | -625.08 Thousand CAD | -128.43% |
| 2018 FY | 1.61 Million CAD | -10.71% |
| 2017 Q2 | 473.52 Thousand CAD | -12.81% |
| 2017 Q3 | 541.34 Thousand CAD | 14.32% |
| 2017 Q4 | 259.16 Thousand CAD | -52.13% |
| 2017 FY | 1.81 Million CAD | 158.53% |
| 2017 Q1 | 543.11 Thousand CAD | 125.39% |
| 2016 Q3 | -156.79 Thousand CAD | 85.28% |
| 2016 Q2 | -1.06 Million CAD | -498.61% |
| 2016 Q1 | 267.31 Thousand CAD | 131.56% |
| 2016 FY | -3.09 Million CAD | -228.58% |
| 2016 Q4 | -2.13 Million CAD | -1264.27% |
| 2015 Q2 | 264.34 Thousand CAD | 215.02% |
| 2015 Q4 | -847.03 Thousand CAD | -555.23% |
| 2015 FY | -941.99 Thousand CAD | -139.22% |
| 2015 Q3 | -129.27 Thousand CAD | -148.9% |
| 2015 Q1 | -229.82 Thousand CAD | 74.74% |
| 2014 Q2 | 431.21 Thousand CAD | -86.18% |
| 2014 Q4 | -909.7 Thousand CAD | -278.8% |
| 2014 Q1 | 3.12 Million CAD | 2472.31% |
| 2014 FY | 2.4 Million CAD | 341.83% |
| 2014 Q3 | -240.15 Thousand CAD | -155.69% |
| 2013 FY | -993.16 Thousand CAD | 75.12% |
| 2013 Q4 | 121.3 Thousand CAD | -49.21% |
| 2013 Q3 | 238.82 Thousand CAD | 142.74% |
| 2013 Q2 | -558.83 Thousand CAD | 29.66% |
| 2013 Q1 | -794.48 Thousand CAD | 57.17% |
| 2012 Q1 | -800.05 Thousand CAD | 38.2% |
| 2012 FY | -3.99 Million CAD | -12.06% |
| 2012 Q4 | -1.85 Million CAD | -153.29% |
| 2012 Q3 | -732.3 Thousand CAD | -21.21% |
| 2012 Q2 | -604.14 Thousand CAD | 24.49% |
| 2011 Q2 | -430.61 Thousand CAD | 31.57% |
| 2011 FY | -3.56 Million CAD | 9.48% |
| 2011 Q1 | -629.24 Thousand CAD | 16.26% |
| 2011 Q4 | -1.29 Million CAD | -7.2% |
| 2011 Q3 | -1.2 Million CAD | -180.43% |
| 2010 Q1 | -443.35 Thousand CAD | 47.5% |
| 2010 FY | -3.93 Million CAD | 19.28% |
| 2010 Q4 | -751.43 Thousand CAD | -16.1% |
| 2010 Q3 | -647.22 Thousand CAD | 69.08% |
| 2010 Q2 | -2.09 Million CAD | -372.06% |
| 2009 FY | -4.87 Million CAD | -30.31% |
| 2009 Q4 | -844.45 Thousand CAD | 29.7% |
| 2009 Q3 | -1.2 Million CAD | 18.93% |
| 2009 Q2 | -1.48 Million CAD | -9.96% |
| 2009 Q1 | -1.34 Million CAD | 16.22% |
| 2008 Q2 | -957.57 Thousand CAD | -41.65% |
| 2008 Q3 | -498.94 Thousand CAD | 47.89% |
| 2008 FY | -3.74 Million CAD | -21.6% |
| 2008 Q4 | -1.6 Million CAD | -222.34% |
| 2008 Q1 | -676 Thousand CAD | 52.56% |
| 2007 Q1 | -401.37 Thousand CAD | 41.38% |
| 2007 Q3 | -742.6 Thousand CAD | -46.37% |
| 2007 Q4 | -1.42 Million CAD | -91.9% |
| 2007 Q2 | -507.35 Thousand CAD | -26.41% |
| 2007 FY | -3.07 Million CAD | -39.52% |
| 2006 FY | -2.2 Million CAD | -18.45% |
| 2006 Q3 | -518.09 Thousand CAD | 7.44% |
| 2006 Q2 | -559.74 Thousand CAD | -26.5% |
| 2006 Q1 | -442.48 Thousand CAD | 54.68% |
| 2006 Q4 | -684.66 Thousand CAD | -32.15% |
| 2005 Q3 | -328.98 Thousand CAD | 13.05% |
| 2005 Q2 | -378.35 Thousand CAD | -112.63% |
| 2005 Q4 | -976.27 Thousand CAD | -196.76% |
| 2005 FY | -1.86 Million CAD | 0.0% |
| 2005 Q1 | -177.93 Thousand CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bioxytran, Inc. | -4.28 Million USD | -4.229% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 94.049% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1531.663% |
| SQZ Biotechnologies Company | -79.46 Million USD | 94.386% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -54.232% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 108.42% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 106.849% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -145.039% |
| Marizyme, Inc. | -65.34 Million USD | 93.173% |
| Genus plc | 7.9 Million USD | 156.468% |
| Pharming Group N.V. | -10.54 Million USD | 57.708% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -105.594% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -20.235% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 49.559% |
| ContraFect Corporation | -65.15 Million USD | 93.153% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -158.241% |
| IMV Inc. | -36.48 Million USD | 87.773% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 44.65% |
| ONE Bio Corp. | 8.67 Million USD | 151.414% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 91.37% |
| Mesoblast Limited | -87.95 Million USD | 94.928% |
| MultiCell Technologies, Inc. | -380.07 USD | -1173630.629% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -19.502% |
| Genscript Biotech Corporation | -95.47 Million USD | 95.328% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -605.4% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -87.368% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 32.164% |
| Biomind Labs Inc. | -1.21 Million USD | -267.366% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -43.821% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 43.554% |
| Skye Bioscience, Inc. | -37.64 Million USD | 88.15% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -128.857% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 59.042% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -29687.647% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 8.7% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 36.115% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 71.893% |
| Accustem Sciences Inc. | -3.74 Million USD | -19.074% |
| EV Biologics, Inc. | -1.26 Million USD | -252.054% |
| Q BioMed Inc. | -2.05 Million USD | -117.388% |
| GB Sciences, Inc. | -1.36 Million USD | -227.611% |
| Alpha Cognition Inc. | -13.77 Million USD | 67.61% |
| CSL Limited | 2.64 Billion USD | 100.169% |
| Agentix Corp. | -1.37 Million USD | -224.622% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 92.531% |
| Enzolytics Inc. | -2.17 Million USD | -104.931% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | -3.61 Million USD | -23.573% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -40.662% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 23.314% |
| argenx SE | -295.05 Million USD | 98.488% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 92.874% |
| HST Global, Inc. | -146.21 Thousand USD | -2951.09% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 4652.039% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -154.221% |
| Halberd Corporation | -79.67 Thousand USD | -5498.923% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 164.423% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -47.416% |
| Zenith Capital Corp. | -10.59 Million USD | 57.899% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -12.283% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -7.599% |
| AVAX Technologies, Inc. | -6.41 Million USD | 30.445% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -7280.796% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -122.481% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -19093.692% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -4.76 Million USD | 6.462% |
| Helix BioMedix, Inc. | -1.05 Million USD | -322.42% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -16.811% |
| Kadimastem Ltd | -3.3 Million USD | -34.879% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | 47.412% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -910.718% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -234.049% |
| LadRx Corporation | 400.44 Thousand USD | 1214.016% |
| Cell Source, Inc. | -5.32 Million USD | 16.166% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -973.7% |
| Regen BioPharma, Inc. | 1.02 Million USD | 535.854% |
| Regen BioPharma, Inc. | 1.02 Million USD | 535.854% |
| Affymax, Inc. | -14.42 Million USD | 69.072% |
| Mobile Lads Corp. | -2.26 Million USD | -97.102% |
| Itoco Inc. | -1.86 Million USD | -138.684% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -0.416% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -167.286% |
| International Stem Cell Corporation | -131 Thousand USD | -3305.342% |
| CytoDyn Inc. | -49.84 Million USD | 91.05% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -5544.475% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1855.489% |
| Qrons Inc. | -789.34 Thousand USD | -465.15% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -373.804% |
| SYBLEU INC | -180.3 Thousand USD | -2374.154% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -113.682% |
| Rebus Holdings, Inc. | -1.02 Million USD | -337.353% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -176.61% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -8119.704% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -76.307% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 90.72% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -111.022% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -471.273% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -40.814% |
| Neutra Corp. | -233.46 Thousand USD | -1810.778% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 78.015% |
| PureTech Health plc | -65.69 Million USD | 93.21% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 79.023% |
| IXICO plc | -1.17 Million USD | -278.693% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 55.062% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 92.191% |
| CSL Limited | 2.64 Billion USD | 100.169% |
| Cellectis S.A. | -103.17 Million USD | 95.676% |